Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns. The Food and Drug Administration is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, opakalim. Opakalim is in testing as a treatment for focal onset seizures. But, in rats, it…
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
Kaynak: Yahoo Finance
İlgili Haberler
Global
Ares Management at td cowen conference: diversification drives growth
Investing.com · 6 dk önce
Global
Perrigo Company stock hits 52-week high at $17.03
Investing.com · 7 dk önce
Global
Accelerant Holdings stock hits 52-week high at 19.91 USD
Investing.com · 7 dk önce
Global
Zymeworks evp Scott Platshon sells $381,535 common stock
Investing.com · 9 dk önce
Global
Alico at 18th annual Southwest IDEAS conference: land pivot gains pace
Investing.com · 11 dk önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.